ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.00 Consensus Target Price from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average recommendation of “Buy” by the four brokerages that are covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have covered the stock in the last year is $80.00.

Several analysts have issued reports on the company. Guggenheim boosted their price target on ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. HC Wainwright boosted their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Truist Financial boosted their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Capital One Financial initiated coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price on the stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 5,692 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $55.95, for a total transaction of $318,467.40. Following the sale, the chief operating officer now directly owns 897,620 shares in the company, valued at $50,221,839. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the transaction, the senior vice president now owns 253,226 shares of the company’s stock, valued at $17,029,448.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Muthusamy Shanmugam sold 5,692 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $55.95, for a total value of $318,467.40. Following the transaction, the chief operating officer now directly owns 897,620 shares in the company, valued at approximately $50,221,839. The disclosure for this sale can be found here. Insiders have sold a total of 138,536 shares of company stock worth $9,013,167 over the last ninety days. Company insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ANIP. China Universal Asset Management Co. Ltd. grew its stake in shares of ANI Pharmaceuticals by 93.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 248 shares during the last quarter. BluePath Capital Management LLC bought a new position in ANI Pharmaceuticals in the third quarter worth approximately $34,000. C M Bidwell & Associates Ltd. bought a new position in ANI Pharmaceuticals in the second quarter worth approximately $35,000. Pacer Advisors Inc. bought a new position in ANI Pharmaceuticals in the fourth quarter worth approximately $41,000. Finally, Point72 Asset Management L.P. grew its stake in ANI Pharmaceuticals by 60.0% in the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 291 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $66.30 on Tuesday. The stock has a 50-day simple moving average of $64.23 and a two-hundred day simple moving average of $58.42. ANI Pharmaceuticals has a 52-week low of $36.99 and a 52-week high of $70.81. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. The firm has a market capitalization of $1.40 billion, a PE ratio of 78.93 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. Analysts forecast that ANI Pharmaceuticals will post 3.55 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.